



[Newest Content](#) [Issues](#) [Special Content](#) [Authors](#) [Subscribers](#) [About](#) [ASCO Publications](#) [Career Center](#) [COVID-19](#)

[Journal of Clinical Oncology](#) > [List of Issues](#) > [Volume 39, Issue 15 suppl](#) >

Meeting Abstract | 2021 ASCO Annual Meeting I

DEVELOPMENTAL THERAPEUTICS—IMMUNOTHERAPY

Phase 1A clinical trial of the first-in-class fascin inhibitor NP-G2-044 evaluating safety and anti-tumor activity in patients with advanced and metastatic solid tumors.



[Vincent Chung](#), [Komal L. Jhaveri](#), [Daniel D. Von Hoff](#), [Xin-Yun Huang](#), [Edward Graeme Garmey](#), [Jillian Zhang](#), ...

[Show More](#)

[Abstract Disclosures](#)

Abstract

2548

Background: Fascin inhibitors block tumor metastasis and increase antigen uptake in intra-tumoral dendritic cells. Filopodia, finger-like protrusions on cell surfaces, are necessary for migration of metastatic tumor cells and intra-tumoral dendritic cells. Fascin is the primary actin cross-linker in filopodia and elevated levels correlate with increased risk of metastasis, disease progression and mortality. NP-G2-044 is a novel small molecule that inhibits function of fascin. Pre-clinical data demonstrate drug-associated reductions in tumor growth and metastasis, enhanced immune response and survival in treated animals, and drug-drug synergism when combined with anti-PD-1 antibodies.

Methods: This multicenter phase 1A clinical trial was designed to evaluate safety and tolerability of NP-G2-044 and to identify the drug's recommended phase 2 dose (RP2D) using a 3+3 dose escalation design. NP-G2-044 was administered to patients (pts.) with treatment-refractory solid tumor malignancies as a single oral daily dose for 6-week cycles that included 4 weeks on (daily dosing) and 2 weeks off (rest). **Results:** A total of 23 pts. were enrolled

OPTIONS & TOOLS

[Export Citation](#)

[Track Citation](#)

[Add To Favorites](#)

[Rights & Permissions](#)

COMPANION ARTICLES

No companion articles

ARTICLE CITATION

DOI: 10.1200/JCO.2021.39.15_suppl.2548
Journal of Clinical Oncology 39, no. 15_suppl
 (May 20, 2021) 2548-2548.

Published online May 28, 2021.

in 7 dose cohorts ranging from 200-2100 mg. QD. Overall, NP-G2-044 appeared well-absorbed and distributed with Tmax of 4 hrs and T1/2 of 20-24 hrs. Across all cohorts, no DLTs, drug-related SAEs or patient deaths were observed. Based on PK and safety findings, 1600 mg. daily was selected as the provisional RP2D. While no formal RECIST-based objective responses were observed, consistent with the drug's non-cytotoxic mechanism of action, preliminary signals of anti-tumor and anti-metastatic activity were observed. These include dose proportional increases in duration of treatment, progression-free-survival, and metastasis-free interval, in particular for 4/4 late-stage ovarian cancer patients (table). Comparison of time on treatment (TOT) for ovarian cancer patients.

Conclusions: In this first-in-human clinical trial, the novel fascin inhibitor, NP-G2-044, appeared safe and well tolerated. Signals of single-drug anti-tumor and anti-metastatic activity were observed. A phase 2A clinical trial with a particular focus on Ovarian Cancer will seek to elucidate signals of RP2D activity in both monotherapy and the combination of NP-G2-044 with anti-PD-(L)1 immune checkpoint inhibitors. [Clinical trial information: NCT03199586.](#)

Patient	Cancer Type	Last Prior Therapy	Time on Last Prior Therapy	Time on NP-G2-044	TOT Improvement	Metastatic Sites Prior to NP-G2-044	New METS on NP-G2-044
023	Ovary	CSF1R Inhibitor	~60 days	170 days	~183%	Liver, Colon, Pancreas, Bladder	No
027	Ovary	Doxorubicin	~105 days	170 days	~62%	Lung, Lymph Node, Peritoneum	No
028	Fallopian Tube	Anti-LIF1	~90 days	158 days	~76%	Lung, Lymph Node	No
031	Ovary	Liposomal Doxorubicin	~90 days	251 days	~179%	Peritoneum, Liver, Abdominal wall, Ilium	No

© 2021 by American Society of Clinical Oncology

ASCO

Hematology/Oncology Program Director

Sayre, Pennsylvania
Compensation and B

Guthrie is seeking to establish the newly Hematology/Oncology

Employer: Guthrie

Medical Oncology Gulf Coast: Infirm

Mobile, Alabama | C & Benefit Package

Medical Oncologist Coast Infirmarey He quality health care larges...

Employer: Infirmarey He

Medical Oncology

Tampa, Florida | As

Research Sponsor:

Novita



QUICK LINKS

Content

Newest Articles
Archive
Meeting Abstracts

Journal Information

About
Editorial Roster
Contact Us
Permissions

Resources

Authors
Reviewers
Subscribers
Institutions
Advertisers

Submit Your Manuscript

Subscribe to this Journal



ASCO FAMILY OF SITES

Journals

Journal of Clinical Oncology
JCO Oncology Practice
JCO Global Oncology
JCO Clinical Cancer Informatics
JCO Precision Oncology

Publications

ASCO Educational Book
ASCO Daily News
ASCO Connection
The ASCO Post

Education

ASCO eLearning
ASCO Meetings
Cancer.Net

Other Sites

ASCO.org
ASCO Author Se
ASCO Career Ce
CancerLinQ
Conquer Cance
TAPUR Study